Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Antidiabetic Drug Dapagliflozin on the Coronary Macrovascular and Microvascular Function in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 2 diabetes mellitus (T2DM) patients presenting with stable angina and a clinical indication for cardiac catheterization~* T2DM patients with non ST elevation myocardial infarction (NSTEMI) or unstable angina referred for cardiac catheterization~* Demonstration of coronary lesion(s) with non-significant fractional flow reserve (FFR) values (\>0.80), for which revascularisation is deferred~* Agreement to practice an acceptable method of birth control for women of childbearing potential~* Signed patient informed consent~Exclusion Criteria:~* Age \< 18 years old~* T2DM patients presenting with ST elevation myocardial infarction (STEMI)~* Pregnancy or breastfeeding~* Body mass index ≥45 kg/m2~* Creatinine clearance ≤45 ml/min/1.73 m2 (as calculated by Modification of Diet in Renal Disease Study (MDRD ) formula for estimated Glomerular filtration rate (GFR))~* Indication of liver disease, defined by serum levels of alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal during screening or run-in phase~* Uncontrolled hyperglycemia with glucose \>240 mg/dL after an overnight fast~* Stroke, or transient ischemic attack at presentation and up to 2 months prior to informed consent~* Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake~* Any uncontrolled endocrine disorder except type 2 diabetes~* Treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent~* Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at time of screening leading to unstable body weight~* Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years~* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells~* Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption~* Planned cardiac surgery or angioplasty within 3 months~* Any clinical condition that would jeopardize patient safety while participating in this clinical trial~* Life expectancy \< 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: PLACEBO_COMPARATOR): The patient will be treated in standard of care for type 2 diabetic mellitus and will receive a placebo (1 tablet) administered orally daily during 24 weeks
- dapagliflozin group (Type: EXPERIMENTAL): The patient will be treated in standard of care for type 2 diabetic mellitus and will receive Dapagliflozin 10 mg (1 tablet) administered orally daily during 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).